Maze therapeutics doses first patient in phase 2 horizon clinical trial evaluating mze829 as a potential treatment for apol1 kidney disease

South san francisco, calif., feb. 07, 2025 (globe newswire) -- maze therapeutics, inc. (nasdaq: maze), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and metabolic diseases, today announced the first patient has been dosed in the company's phase 2 clinical trial, the horizon study, of mze829 in patients with apol1 kidney disease (akd).
MAZE Ratings Summary
MAZE Quant Ranking